Recent progress in PYY research-An update report for 8th NPY meeting

Peptides

Volumn 28, Issue 2, 2007, Pages 198-202

  Ashby, D ^a   Bloom, S R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Appetite; Gastrointestinal hormone; Obesity; Peptide YY

Indexed keywords

ANOREXIGENIC AGENT; ANTIOBESITY AGENT; CAPSAICIN; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LACTITOL; LEPTIN; LIPID; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; PEPTIDE YY; PEPTIDE YY [3-36]; PROTEIN FOS; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ANOREXIA; APPETITE; CLINICAL TRIAL; CONFERENCE PAPER; ENERGY BALANCE; GENETIC VARIABILITY; HORMONAL REGULATION; HUMAN; NONHUMAN; OBESITY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; SENSORY NERVE; STOMACH BYPASS; VAGUS NERVE; WEIGHT REDUCTION;

ANIMALS; APPETITE; CLINICAL TRIALS; HUMANS; PEPTIDE YY;

RODENTIA;

EID: 33846585956     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2006.10.019     Document Type: Conference Paper

References (67)

1. Nastech Press Release. March 2, 2006.
2. Abbott C.R., Monteiro M., Small C.J., Sajedi A., Smith K.L., Parkinson J.R., et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044 (2005) 127-131
3. Abbott C.R., Small C.J., Kennedy A.R., Neary N.M., Sajedi A., Ghatei M.A., et al. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res 1043 (2005) 139-144
4. Adams S.H., Lei C., Jodka C.M., Nikoulina S.E., Hoyt J.A., Gedulin B., et al. PYY[3-36] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice. J Nutr 136 (2006) 195-201
5. Adrian T.E., Ferri G.L., Bacarese-Hamilton A.J., Fuessl H.S., Polak J.M., and Bloom S.R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89 (1985) 1070-1077
6. Adrian T.E., Savage A.P., Bacarese-Hamilton A.J., Wolfe K., Besterman H.S., and Bloom S.R. Peptide YY abnormalities in gastrointestinal diseases. Gastroenterology 90 (1986) 379-384
7. Ahituv N., Kavaslar N., Schackwitz W., Ustaszewska A., Collier J.M., Hebert S., et al. A PYY Q62P variant linked to human obesity. Hum Mol Genet 15 (2006) 387-391
8. Akanmu M.A., Ukponmwan O.E., Katayama Y., and Honda K. Neuropeptide-Y Y(2)-receptor agonist, PYY(3-36) promotes non-rapid eye movement sleep in rat. Neurosci Res 54 (2006) 165-170
9. Babu M., Purhonen A.K., Bansiewicz T., Makela K., Walkowiak J., Miettinen P., et al. Effect of total colectomy and PYY infusion on food intake and body weight in rats. Regul Pept 131 (2005) 29-33
10. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349 (2003) 941-948
11. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418 (2002) 650-654
12. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418 (2002) 650-654
13. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418 (2002) 650-654
14. Brunetti L., Orlando G., Ferrante C., Chiavaroli A., and Vacca M. Peptide YY(3-36) inhibits dopamine and norepinephrine release in the hypothalamus. Eur J Pharmacol 519 (2005) 48-51
15. Carmosino M., Mazzone A., Laforenza U., Gastaldi G., Svelto M., and Valenti G. Altered expression of aquaporin 4 and H(+)/K(+)-ATPase in the stomachs of peptide YY (PYY) transgenic mice. Biol Cell 97 (2005) 735-742
16. Challis B.G., Coll A.P., Yeo G.S., Pinnock S.B., Dickson S.L., Thresher R.R., et al. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc Natl Acad Sci USA 101 (2004) 4695-4700
17. Challis B.G., Pinnock S.B., Coll A.P., Carter R.N., Dickson S.L., and O'Rahilly S. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 311 (2003) 915-919
18. Challis B.G., Pinnock S.B., Coll A.P., Carter R.N., Dickson S.L., and O'Rahilly S. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 311 (2003) 915-919
19. Chan J.L., Stoyneva V., Kelesidis T., Raciti P., and Mantzoros C.S. Peptide YY levels are decreased by fasting and elevated following caloric intake but are not regulated by leptin. Diabetologia 49 (2006) 169-173
20. Chelikani P.K., Haver A.C., Reeve Jr. J.R., Keire D.A., and Reidelberger R.D. Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats. Am J Physiol Regul Integr Comp Physiol 290 (2006) R298-R305
21. cuna-Goycolea C., Tamamaki N., Yanagawa Y., Obata K., and van den Pol A.N. Mechanisms of neuropeptide Y, peptide YY, and pancreatic polypeptide inhibition of identified green fluorescent protein-expressing GABA neurons in the hypothalamic neuroendocrine arcuate nucleus. J Neurosci 25 (2005) 7406-7419
22. cuna-Goycolea C., and van den Pol A.N. Peptide YY(3-36) inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis. J Neurosci 25 (2005) 10510-10519
23. Daousi C., MacFarlane I.A., English P.J., Wilding J.P., Patterson M., Dovey T.M., et al. Is there a role for ghrelin and peptide-YY in the pathogenesis of obesity in adults with acquired structural hypothalamic damage?. J Clin Endocrinol Metab 90 (2005) 5025-5030
24. Davis J., Hickner R.C., Tanenberg R.J., and Barakat H. Peptide-YY levels after a fat load in black and white women. Obes Res 13 (2005) 2055-2057
25. Degen L., Oesch S., Casanova M., Graf S., Ketterer S., Drewe J., et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 129 (2005) 1430-1436
26. Di F.V., Zamboni M., Dioli A., Zoico E., Mazzali G., Omizzolo F., et al. Delayed postprandial gastric emptying and impaired gallbladder contraction together with elevated cholecystokinin and peptide YY serum levels sustain satiety and inhibit hunger in healthy elderly persons. J Gerontol A: Biol Sci Med Sci 60 (2005) 1581-1585
27. Feinle-Bisset C., Patterson M., Ghatei M.A., Bloom S.R., and Horowitz M. Fat digestion is required for suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid. Am J Physiol Endocrinol Metab 289 (2005) E948-E953
28. Fu-Cheng X., Anini Y., Chariot J., Castex N., Galmiche J.P., and Roze C. Mechanisms of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gut. Pflugers Arch 433 (1997) 571-579
29. Gee J.M., and Johnson I.T. Dietary lactitol fermentation increases circulating peptide YY and glucagon-like peptide-1 in rats and humans. Nutrition 21 (2005) 1036-1043
30. Ghamari-Langroudi M., Colmers W.F., and Cone R.D. PYY3-36 inhibits the action potential firing activity of POMC neurons of arcuate nucleus through postsynaptic Y2 receptors. Cell Metab 2 (2005) 191-199
31. Goldstone A.P., Patterson M., Kalingag N., Ghatei M.A., Brynes A.E., Bloom S.R., et al. Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab 90 (2005) 2681-2690
32. Halatchev I.G., and Cone R.D. Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice. Cell Metab 1 (2005) 159-168
33. Halatchev I.G., Ellacott K.L., Fan W., and Cone R.D. Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145 (2004) 2585-2590
34. Halatchev I.G., Ellacott K.L., Fan W., and Cone R.D. Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145 (2004) 2585-2590
35. Kim B.J., Carlson O.D., Jang H.J., Elahi D., Berry C., and Egan J.M. Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab 90 (2005) 6665-6671
36. Kim H., Whang W.W., Kim H.T., Pyun K.H., Cho S.Y., Hahm D.H., et al. Expression of neuropeptide Y and cholecystokinin in the rat brain by chronic mild stress. Brain Res 983 (2003) 201-208
37. Koda S., Date Y., Murakami N., Shimbara T., Hanada T., Toshinai K., et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 146 (2005) 2369-2375
38. Koegler F.H., Enriori P.J., Billes S.K., Takahashi D.L., Martin M.S., Clark R.L., et al. Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. Diabetes 54 (2005) 3198-3204
39. Kojima S., Nakahara T., Nagai N., Muranaga T., Tanaka M., Yasuhara D., et al. Altered ghrelin and peptide YY responses to meals in bulimia nervosa. Clin Endocrinol (Oxf) 62 (2005) 74-78
40. le Roux C.W., Aylwin S.J., Batterham R.L., Borg C.M., Coyle F., Prasad V., et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243 (2006) 108-114
41. le Roux C.W., Batterham R.L., Aylwin S.J., Patterson M., Borg C.M., Wynne K.J., et al. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147 (2006) 3-8
42. le Roux C.W., Ghatei M.A., Gibbs J.S., and Bloom S.R. The putative satiety hormone PYY is raised in cardiac cachexia associated with primary pulmonary hypertension. Heart 91 (2005) 241-242
43. Lin S., Boey D., Couzens M., Lee N., Sainsbury A., and Herzog H. Compensatory changes in [125I]-PYY binding in Y receptor knockout mice suggest the potential existence of further Y receptor(s). Neuropeptides 39 (2005) 21-28
44. Ma L., Tataranni P.A., Hanson R.L., Infante A.M., Kobes S., Bogardus C., et al. Variations in peptide YY and Y2 receptor genes are associated with severe obesity in Pima Indian men. Diabetes 54 (2005) 1598-1602
45. Martin J.R. Peptide YY administration into the posterior hypothalamic nucleus of the rat evokes cardiovascular changes by non-adrenergic, non-cholinergic mechanisms. Auton Autacoid Pharmacol 25 (2005) 53-67
46. Martin N.M., Small C.J., Sajedi A., Patterson M., Ghatei M.A., and Bloom S.R. Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY(3-36) but resistant to ghrelin. Int J Obes Relat Metab Disord 28 (2004) 886-893
47. Misra M., Miller K.K., Tsai P., Gallagher K., Lin A., Lee N., et al. Elevated Peptide YY Levels in Adolescent Girls with Anorexia Nervosa. J Clin Endocrinol Metab 91 (2006) 1027-1033
48. Monteleone P., Martiadis V., Rigamonti A.E., Fabrazzo M., Giordani C., Muller E.E., et al. Investigation of peptide YY and ghrelin responses to a test meal in bulimia nervosa. Biol Psychiatry 57 (2005) 926-931
49. Moran T.H., Smedh U., Kinzig K.P., Scott K.A., Knipp S., and Ladenheim E.E. Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 288 (2005) R384-R388
50. Morinigo R., Moize V., Musri M., Lacy A.M., Navarro S., Luis M.J., et al. GLP-1, PYY, hunger and satiety following gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 91 (2006) 1735-1740
51. Neary N.M., Small C.J., Druce M.R., Park A.J., Ellis S.M., Semjonous N.M., et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 146 (2005) 5120-5127
52. Pilichiewicz A.N., Little T.J., Brennan I.M., Meyer J.H., Wishart J.M., Otto B., et al. Effects of load, and duration, of duodenal lipid on antropyloroduodenal motility, plasma CCK and PYY, and energy intake in healthy men. Am J Physiol Regul Integr Comp Physiol 290 (2006) R668-R677
53. Pittner R.A., Moore C.X., Bhavsar S.P., Gedulin B.R., Smith P.A., Jodka C.M., et al. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 28 (2004) 963-971
54. Riediger T., Bothe C., Becskei C., and Lutz T.A. Peptide YY directly inhibits ghrelin-activated neurons of the arcuate nucleus and reverses fasting-induced c-Fos expression. Neuroendocrinology 79 (2004) 317-326
55. Roth C.L., Enriori P.J., Harz K., Woelfle J., Cowley M.A., and Reinehr T. Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss. J Clin Endocrinol Metab 90 (2005) 6386-6391
56. Schonhoff S., Baggio L., Ratineau C., Ray S.K., Lindner J., Magnuson M.A., et al. Energy homeostasis and gastrointestinal endocrine differentiation do not require the anorectic hormone peptide YY. Mol Cell Biol 25 (2005) 4189-4199
57. Scott V., Kimura N., Stark J.A., and Luckman S.M. Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour. J Neuroendocrinol 17 (2005) 452-457
58. Shechter Y., Tsubery H., Mironchik M., Rubinstein M., and Fridkin M. Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice. FEBS Lett 579 (2005) 2439-2444
59. Siahanidou T., Mandyla H., Vounatsou M., Anagnostakis D., Papassotiriou I., and Chrousos G.P. Circulating peptide YY concentrations are higher in preterm than full-term infants and correlate negatively with body weight and positively with serum ghrelin concentrations. Clin Chem 51 (2005) 2131-2137
60. Sileno A.P., Brandt G.C., Spann B.M., and Quay S.C. Lower mean weight after 14 days intravenous administration peptide YY3-36 (PYY3-36) in rabbits. Int J Obes (Lond) 30 (2006) 68-72
61. Stock S., Leichner P., Wong A.C., Ghatei M.A., Kieffer T.J., Bloom S.R., et al. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab 90 (2005) 2161-2168
62. Symersky T., Biemond I., Frolich M., and Masclee A.A. Effect of peptide YY on pancreatico-biliary secretion in humans. Scand J Gastroenterol 40 (2005) 944-949
63. Talebizadeh Z., Kibiryeva N., Bittel D.C., and Butler M.G. Ghrelin, peptide YY and their receptors: gene expression in brain from subjects with and without Prader-Willi syndrome. Int J Mol Med 15 (2005) 707-711
64. Talsania T., Anini Y., Siu S., Drucker D.J., and Brubaker P.L. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146 (2005) 3748-3756
65. Tatemoto K., and Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 285 (1980) 417-418
66. Torekov S.S., Larsen L.H., Glumer C., Borch-Johnsen K., Jorgensen T., Holst J.J., et al. Evidence of an association between the Arg72 allele of the peptide YY and increased risk of type 2 diabetes. Diabetes 54 (2005) 2261-2265
67. Tschop M., Castaneda T.R., Joost H.G., Thone-Reineke C., Ortmann S., Klaus S., et al. Physiology: does gut hormone PYY3-36 decrease food intake in rodents?. Nature 430 (2004) 431